

# Radioligands for the study of brain 5-HT<sub>1A</sub> receptors *in vivo*—development of some new analogues of way

Victor W. Pike<sup>1</sup>, Christer Halldin<sup>b</sup>, Håkan Wikström<sup>c</sup>, Sandrine Marchais<sup>c</sup>, Julie A. McCarron<sup>1</sup>, Johan Sandell<sup>b</sup>, Bartek Nowicki<sup>c</sup>, Carl-Gunnar Swahn<sup>b</sup>, Safiye Osman<sup>1</sup>, Susan P. Hume<sup>1</sup>, Maria Constantinou<sup>1</sup>, Bengt Andréé<sup>b</sup> and Lars Farde<sup>b</sup>

<sup>1</sup> MRC Cyclotron Unit, Imperial College School of Medicine, Hammersmith Hospital, Ducane Road, London W12 ONN, United Kingdom

<sup>b</sup> Karolinska Institutet, Department of Clinical Neuroscience, Psychiatry Section, S-17176 Stockholm, Sweden

<sup>c</sup> University Centre for Pharmacy, University of Groningen, Groningen, The Netherlands

„...Calculated from Pallas 2.1 for Windows (**Compudrug**). b Reference 4 . c Reference 25 . d...hydrolysis being the primary route of **metabolism**. However, the kinetic behaviour of DWAY...additional benefit of less susceptibility to **metabolism** than WAY, DWAY, or C6BPWAY. The results...”

## Abstract

ABSTRACT. [*Carbonyl*-<sup>11</sup>C]WAY-100635 (WAY) has proved to be a very useful radioligand for the imaging of brain 5-HT<sub>1A</sub> receptors in human brain *in vivo* with positron emission tomography (PET). WAY is now being applied widely for clinical research and drug development. However, WAY is rapidly cleared from plasma and is also rapidly metabolised. A comparable radioligand, with a higher and more sustained delivery to brain, is desirable since these properties might lead to better biomathematical modelling of acquired PET data. There are also needs for other types of 5-HT<sub>1A</sub> receptor radioligands, for example, ligands sensitive to elevated serotonin levels, ligands labelled with longer-lived fluorine-18 for distribution to "satellite" PET centres, and ligands labelled with iodine-123 for single photon emission computerised tomography (SPECT) imaging. Here we describe our progress toward these aims through the exploration of WAY analogues, including the development of [*carbonyl*-<sup>11</sup>C]desmethyl-WAY (DWAY) as a promising, more brain-penetrant radioligand for PET imaging of human 5-HT<sub>1A</sub> receptors, and (*pyridinyl*-6-halo)-analogues as promising leads for the development of radiohalogenated ligands.

**Author Keywords:** WAY; Radioligands; 5-HT<sub>1A</sub> receptors; Brain; PET; Carbon-11; Fluorine-18

[Nuclear Medicine and Biology](#)

[Volume 27, Issue 5](#) , July 2000, Pages 449-455